Free Trial
NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Price, News & Analysis

Evoke Pharma logo
$3.18 -0.28 (-8.06%)
As of 12:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Evoke Pharma Stock (NASDAQ:EVOK)

Key Stats

Today's Range
$3.33
$3.63
50-Day Range
$2.07
$3.82
52-Week Range
$1.94
$12.32
Volume
6,385 shs
Average Volume
123,102 shs
Market Capitalization
$4.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Stock News Headlines

Trump’s Strange “Midnight Tweet” Could Trigger Massive Gains
President Trump sends out explosive tweets at all hours of the day... And the market reacts violently. According to one Wall Street legend, Americans can target as much as 627% within HOURS. You have to see how to target these massive profits (from Trump’s latest tweets) for yourself....
Q4 2024 Evoke Pharma Inc Earnings Call
See More Headlines

EVOK Stock Analysis - Frequently Asked Questions

Evoke Pharma's stock was trading at $4.42 at the start of the year. Since then, EVOK stock has decreased by 28.0% and is now trading at $3.1810.
View the best growth stocks for 2025 here
.

Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings results on Monday, May, 12th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.18. The specialty pharmaceutical company earned $3.08 million during the quarter, compared to the consensus estimate of $3.32 million. Evoke Pharma had a negative trailing twelve-month return on equity of 308.49% and a negative net margin of 71.32%.

Shares of Evoke Pharma reverse split on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
5/12/2025
Today
6/06/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.79 million
Pretax Margin
-71.32%

Debt

Sales & Book Value

Annual Sales
$11.59 million
Price / Cash Flow
N/A
Book Value
($9.26) per share
Price / Book
-0.37

Miscellaneous

Free Float
1,395,000
Market Cap
$5.17 million
Optionable
Not Optionable
Beta
0.16

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:EVOK) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners